|
Parameter
|
HeFH (n = 10)
|
HeFH (n = 10)
|
HoFH (n = 4)
|
HoFH (n = 4)
|
|---|
|
Lipids, mmol/L
|
Decrease, n (%)
|
Mean decrease (SD)/year
|
Decrease, n (%)
|
Mean decrease (SD)/year
|
|---|
|
TC
|
8 (80)
|
0.18 (0.08)
|
4 (100)
|
0.93 (1.2)
|
|
LDL-C
|
6 (60)
|
0.18 (0.06)
|
2 (50)
|
0.37 (0.19)
|
|
HDL-C
|
5 (50)
|
0.04 (0.01)
|
2 (50)
|
0.04 (0.01)
|
|
apoB
|
1 (10)
|
0.06 (0)
|
0 (0)
|
–
|
|
Soluble endoglin, ng/mL
|
3 (30)
|
0.37 (0.15)
|
1 (25)
|
0.52 (0)
|
|
CD40L, pg/mL
|
3 (30)
|
714 (193)
|
2 (50)
|
477 (122)
|
|
hsCRP, mg/L
|
0 (0)
|
–
|
3 (75)
|
0.62 (0.49)
|
|
MCP-1, pg/mL
|
3 (30)
|
27.29 (4.84)
|
1 (25)
|
15.99 (0)
|
|
sP-selectin, ng/mL
|
4 (40)
|
9.92 (6.43)
|
0 (0)
|
–
|
- Data shows how many patients LA resulted in the change of studied parameters. Moreover, we show an average yearly reduction of levels/biomarkers after LA (where the average is computed over those patients exhibiting a statistically significant reduction)
